"Johnson & Johnson's Q1 Earnings Surge on Strong Medical Device Sales, Talc Issues Loom"
TL;DR Summary
Johnson & Johnson reported first-quarter earnings that surpassed Wall Street estimates, with adjusted EPS of $2.71 and sales of $21.38 billion, driven by strong performance in its medical devices and innovative medicine segments. The company also raised its quarterly dividend and provided an upbeat outlook for fiscal year 2024.
- Johnson & Johnson Q1 Earnings Top Wall Street Estimates On Strong Medical Devices Sales, Drugmaker Boosts Benzinga
- Johnson & Johnson tops quarterly profit estimates as medical device sales jump CNBC
- Johnson & Johnson Stock Falls After Earnings Beat. Talc Issues Loom. Barron's
- J&J's medical device sales fall short, cancer drugs seen growing Reuters
- Read About Johnson & Johnson's 2024 First-Quarter Earnings Johnson & Johnson
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
1 min
vs 2 min read
Condensed
84%
297 → 49 words
Want the full story? Read the original article
Read on Benzinga